Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Xintela AB
XINTXintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Analytics
Precio Objetivo de WallStreet
–Relación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave XINT
Análisis de dividendos XINT
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout XINT
Valoración de la acción XINT
Finanzas XINT
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |